 |
|
|
| |
New HCV Drugs at EASL
|
| |
| |
From Jules: Roche, Abbott and GNS-227 appear to have 2nd generation protease inhibitors. There were several new NS5As and nucleotides presented besides the Pharmasset impressive data on their 2 nucleotides which are the furthest along in development including by Abbott & Intermune. TMC435 & BI201335 are in phase 3. The DEBO25 cyclophilin inhibitor looked good in large phase 2 study and is also in phase 3. Several companies repo
EASL: HCV Cured With out Peginterferon/ribavirin with 2 oral HCV drugs BMS790052+BMS650032: Quadruple Therapy With BMS-790052, BMS-650032 and Peg-IFN/RBV for 24 Weeks Results in 100% SVR12 in HCV Genotype 1 Null Responders: "HCV infection can be cured without interferon & ribavirin: 2 orals BMS790052+BMS650032" - (04/02/11)
EASL: 4 New HCV Drugs: 1st SVR Results from NS5A BMS790052; 2 nucleotides in combination PSI938 + PSI7977; cyclophillin inhibitor Debo25; - (03/31/11)
EASL: PROTON Study: PSI-7977 QD with PEG/RBV: 12-week Safety, RVR, cEVR, & SVR12 in Treatment-naïve Patients with HCV GT2 or GT3 - (04/01/11)
EASL: ONCE DAILY DUAL-NUCLEOTIDE COMBINATION OF PSI-938 AND PSI-7977 PROVIDES 94% HCV RNA < LOD AT DAY 14: FIRST PURINE/PYRIMIDINE CLINICAL COMBINATION DATA (THE NUCLEAR STUDY) - (03/31/11)
EASL: PSI-7977 QD Plus PEG/RBV In HCV GT1: 98% Rapid Virologic Response, Complete Early Virologic Response: The PROTON Study - (03/31/11)
EASL: Pharmasset Initiates Phase 2b ATOMIC Trial of PSI-7977 for Multiple HCV Genotypes - (03/31/11)
EASL: TMC435 HCV Protease - (04/04/11)
EASL: SILEN-C1: sustained virological response (SVR) and safety of BI 201335 combined with peginterferon alfa 2a and ribavirin (PegIFN/RBV) in treatment-naïve patients with chronic genotype-1 HCV infection - (04/01/11)
EASL: SILEN-C2: sustained virological response (SVR) and safety of BI 201335 combined with peginterferon alfa 2a and ribavirin (PegIFN/RBV) in chronic HCV genotype-1 patients with nonresponse to PegIFN/RBV - (04/01/11)
EASL: Once daily alisporivir (DEB025) plus Peg-IFN-alfa-2A/ ribavirin results in superior sustained virologic response (SVR24) in chronic hepatitis C genotype 1 treatment-naïve patients - The ESSENTIAL study - (03/31/11) Novartis press release
EASL: Once daily alisporivir (DEB025) plus Peg-IFN-alfa-2A/ ribavirin results in superior sustained virologic response (SVR24) in chronic hepatitis C genotype 1 treatment-naïve patients - The ESSENTIAL study - (03/31/11)
EASL: BMS-650032, an NS3 Inhibitor (protease), in Combination With Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Subjects With Genotype 1 Chronic Hepatitis C Infection - (04/08/11)
EASL: First Report of SVR12 for a NS5A Replication Complex Inhibitor, BMS-790052, in Combination With PegIFNα-2a and RBV: Phase IIA Trial in Treatment-Naive HCV Genotype 1 Subjects - (03/31/11)
EASL: Interim Phase 2 Data Showed Rapid Viral Response to VX-222 in Combination with Telaprevir, Pegylated-Interferon and Ribavirin Among People With Hepatitis C - (03/31/11) vertex press release
EASL: Activity of danoprevir plus low-dose ritonavir in combination with peginterferon alfa-2a (40KD) plus ribavirin in previous null responders - (04/01/11)
EASL: BMS-766, a Novel HCV NS5A Inhibitor With Enhanced Resistance Coverage - (04/06/11)
EASL: Pegylated Interferon-Lambda (PegIFN-λ) Shows Superior Viral Response With Improved Safety and Tolerability Versus PegIFN-α-2a in HCV Patients (G1/2/3/4): EMERGE Phase IIb Through Week 12 - (04/03/11)
EASL: Investigational Compound PEG-Interferon Lambda Achieved Higher Response Rates with Fewer Flu-Like and Musculoskeletal Symptoms and Cytopenias Than PEG-Interferon Alfa in Phase IIb Study of 526 Treatment-Naive Hepatitis C Patients - BMS press release - (04/03/11)
EASL: Characterization of Virologic Escape in HCV Genotype 1 Null Responders Receiving a Combination of the NS3 Protease Inhibitor BMS-650032 and NS5A Inhibitor BMS-790052 - (04/05/11)
EASL: First SVR data with the nucleoside analogue polymerase inhibitor mericitabine (RG7128) combined with peginterferon/ribavirin in treatment-naive HCV G1/4 patients: interim analysis from the JUMP-C trial - (04/03/11)
ABT-450/Ritonavir (ABT-450/r) Combined with Pegylated Interferon Alpha-2a and Ribavirin After 3-Day Monotherapy in Genotype 1 HCV-Infected Treatment-naïve Subjects: 12-Week Interim Efficacy and Safety Results - (04/04/11)
EASL: Genotypic and Phenotypic Characterization of NS3 Variants Selected in HCV-Infected Patients Treated with ABT-450 - (04/05/11)
Boosted ABT-450/r HCV Protease 3-Day Monotherapy - (04/04/11)
EASL: Factors affecting HCV viral load response to the non-nucleoside polymerase inhibitors ABT-072 and ABT-333 - (04/05/11)
Danoprevir Unboosted activity, safety & resistance - (04/04/11)
EASL: Low prevalence of danoprevir resistance identified in genotype 1b HCV patients with prior null response treated with danoprevir plus low-dose ritonavir plus peginterferon alfa-2a (40KD)/ribavirin for 12 weeks - (04/06/11)
Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN _-2a/RBV in hepatitis C patients - pdf attached - (04/04/11)
EASL: In vitro profiling of GSK2336805, A Potent and Selective Inhibitor of HCV NS5A - (04/08/11)
EASL: Preclinical Characterization of GSK2485852A, a Novel HCV Polymerase Inhibitor - (04/08/11)
EASL: Treatment outcome and resistance analysis in HCV genotype 1 patients previously exposed to TMC435 monotherapy and re-treated with TMC435 in combination with PegIFNa-2a/ribavirin - (04/08/11)
EASL: Gilead's HCV Pipeline Unveiled at EASL - (04/13/11)
EASL: NOVEL, POTENT, PAN-GENOTYPIC HCV NS3/4A PROTEASE INHIBITORS WITH A HIGH BARRIER TO RESISTANCE - 2nd generation protease - Roche/Intermune - (04/09/11)
EASL: Inhibitex Reports Positive Safety and Antiviral Data from Its Phase 1b Study of HCV Nucleotide Inhibitor INX-189 - (04/11/11)
EASL: A Study of the Safety and Pharmacokinetics of Single Ascending Oral Doses of INX-08189, a Nucleotide Polymerase Inhibitor, in Healthy Subjects - (04/11/11)
EASL: No resistance to IDX184 was detected in 3-day and 14-day clinical studies of IDX184 in genotype 1-infected HCV subjects - (04/11/11)
EASL: Idenix NS5A HCV replication inhibitors with low picomolar, pan-genotypicin vitro antiviral activity - (04/11/11)
EASL: CHARACTERIZATION OF NOVEL, HIGHLY POTENT NS5A INHIBITORS WITH QD DOSING POTENTIAL AND ROBUST ACTIVITY IN AN HCV CHIMERIC ANIMAL MODEL Intermune - (04/11/11)
EASL: GNS-227: A New Potent and Selective (2nd Gen) HCV NS3 Protease Inhibitor With a High Genetic Barrier to Resistance - (04/11/11)
EASL: ACH-2928: A NOVEL HIGHLY POTENT HCV NS5A INHIBITOR WITH FAVORABLE PRECLINICAL CHARACTERISTICS - (04/11/11)
EASL: Achillion Announces Positive RVR Results With ACH-1625 to Treat Chronic Hepatitis C - (03/30/11)
EASL: PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY AND TOLERABILITY OF ACH-1625 (HCV NS3 PROTEASE INHIBITOR) IN HCV GENOTYPE 1 INFECTION - (04/11/11)
EASL: CHARACTERIZATION AND IDENTIFICATION OF PPI-437, PPI-668 AND PPI-833 AS POTENT AND SELECTIVE HCV NS5A INHIBITORS WITH ACTIVITY AGAINST ALL HCV GENOTYPES - (04/11/11)
EASL: Presidio Pharmaceuticals, Inc. Announces Positive Results in a Phase 1b Clinical Trial of PPI-461, a Novel, Potent Broadly-Active Hepatitis C Virus (HCV) Inhibitor - (03/30/11)
|
| |
|
|
|
|
|
